Recruiting
Phase 2

Ascorbate with Gemcitabine/Carboplatin

Sponsor:

University of Kansas Medical Center

Code:

NCT06493370

Conditions

Bladder Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Intravenous ascorbic acid/vitamin C

Study Details

Brief summary:

This is a phase II, single arm, Simon two-stage design, trial, enrolling patients with cisplatin ineligible MIBC and/or those patients who decline cisplatin based NAC.

Assess rates of pathologic downstaging and quality of life in MIBC cisplatin-ineligible/declined patients when IVC is added to gemcitabine-carboplatin NAC.

Conditions

Bladder Cancer

Study ID

NCT06493370

Start date

Jan 16, 2025

Status verified date

Jul, 2024

Completion date

Dec 1, 2030

Anticipated

Primary completion date

Dec 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ability of participant to understand this study, and participant willingness to sign a written informed consent
  • Consent to participate in biorepository protocol number GUB-BCR-001, KU IRB Approved HSC # STUDY00141546
  • Males and females age ≥ 18 years
  • ECOG Performance Status (PS) 0 - 2
  • Women of childbearing potential must have a negative serum pregnancy test 72 hours prior to initiating treatment.
  • Diagnosis/disease status Cisplatin-ineligible or declined muscle invasive bladder cancer. Cisplatin ineligibility will be defined based on Galsky criteria: CTCAE ver. 5.0 Grade 2 or greater peripheral neuropathy; CTCAE ver. 5.0 Grade 2 or greater hearing loss; Creatinine clearance estimated or calculated < 60 ml/min; NYHA class II or greater congestive heart failure
  • Adequate organ function, defined as follows: Absolute Neutrophil Count >1.5K/UL. (NOTE: Patients with established diagnosis of benign neutropenia are eligible to participate with ANC between 1000-1500 based on discretion of the treating physician.); Platelets >100K/UL; Hemoglobin ≥ 9 g/dL; Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation; Total bilirubin ≤ 2.0 x ULN; Aspartate aminotransferase (AST \[SGOT\]) and alanine aminotransferase (ALT \[SGPT\]) ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN; Normal Glucose-6-phosphate dehydrogenase (G6PD) status
  • Women of child-bearing potential (WOCBP) and men with partners of child-bearing potential must agree not to donate sperm (men), to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation and for WOMEN: 6 months after EOT, MEN: 3 months after EOT following completion of therapy.

Exclusion Criteria:

  • Simultaneously enrolled in any therapeutic clinical trial
  • Current or anticipating use of other anti-neoplastic or investigational agents while participating in this study
  • Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
  • Is pregnant or breastfeeding. There is a potential for congenital abnormalities and for this regimen to harm breast feeding infants
  • Women of childbearing age expecting to conceive children while receiving study treatment and for 6 months after the last dose of study treatment. Men expecting to conceive children while receiving study treatment and for 3 months after the last dose of study treatment
  • Has a severe known allergic reaction to any excipient contained in the study drug formulation
  • Active Grade 3 or 4 (per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0109) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment.
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, as determined per treating physician.
  • Histology of pure adenocarcinoma, pure squamous cell carcinoma, or pure small cell carcinoma in the TURBT sample
  • Current consumption of tobacco products, patients may be asked to quit for 2 weeks prior to enrollment
  • If tobacco use is suspected at any point during the trial, cotinine level will be obtained
  • History of G6PD deficiency
  • History of oxalate renal calculi - per discretion of treating physician

Study Design

Enrollment

48 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Intravenous ascorbic acid/vitamin C

2 Cycles Carboplatin Day 1 and Gemcitabine Days 1 and 8 (NAC)

+ Intravenous Vitamin C Days 1-28

Interventions

Intravenous ascorbic acid/vitamin C

A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles

Primary outcome measure

  • Post treatment pathological staging [ Time Frame: Approximately 10 to 12 weeks ]

Central Contacts and Locations

Central contacts

KUCC Navigation

913-588-3671kucc_navigation@kumc.edu

Faith Rahman

913-588-2502frahman2@kumc.edu

Locations

The University of Kansas Cancer Center

Recruiting

Kansas City, Kansas, United States, 66160

Contacts

KUCC Navigation

913-588-3671kucc_navigation@kumc.edu

Principal Investigator:

John Taylor III, MD, MS

More Information

Sponsor

University of Kansas Medical Center

Last update posted

Feb 20, 2025

Last verified

Jul, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Kansas Medical Center on 2025-02-20.